[1] Chen WJ, Lai SJ, Yang Y, et al.Mapping the distribution of anthrax in mainland China, 2005-2013[J]. PLoS Negl Trop Dis,2016,10(4): e0004637.
[2] Yu D, He J, Zhang E, et al.Investigation and source-tracing of an?anthrax outbreak in Gansu Province, China[J].PLoS One,2018,13(8):e0203267.
[3] 中华人民共和国国家卫生部. WS 283—2008炭疽诊断标准[S].北京:人民卫生出版社,2008.
[4] 李梦东,王宇明.实用传染病学[M].北京,人民卫生出版社,2005:903-908.
[5] Makdasi E, Laskar O, Glinert I, et al.Rapid and sensitive multiplex assay for the detection of b. anthracis spores from environmental samples[J].Pathogens,2020,9(3): 164.
[6] Solano MI, Woolfitt AR, Boyer AE,et al.Accurate and selective quantification of anthrax protective antigen in plasma by immunocapture and isotope dilution mass spectrometry[J].Analyst,2019,144(7):2264-2274.
[7] Doganay M, Demiraslan H.Human anthrax as a re-emerging disease[J].Recent Pat Antiinfect Drug Discov,2015,10(1):10-29.
[8] Vieira AR, Salzer JS, Traxler RM,et al.Enhancing surveillance and diagnostics in anthrax-endemic countries[J].Emerg Infect Dis,2017,23(Suppl 1): S147-S153.
[9] Zhang WY, Wang LY, Zhang XS, et al.Spatiotemporal clustering analysis and risk assessments of human cutaneous anthrax in China, 2005-2012[J].PLoS One,2015,10(7):e0133736.
[10] Manzulli V, Fasanella A, Parisi A, Evaluation of in vitro antimicrobial susceptibility of bacillus anthracis strains isolated during anthraxoutbreaks in Italy from 1984 to 2017[J].J Vet Sci,2019,20(1):58-62.
[11] Stratilo CW, Jager S, Crichton M, Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax[J].PLoS One,2020,15(1):e0228162.
[12] Shali A, Hasannia S, Gashtasbi F, et al.Generation and screening of efficient neutralizing single domain antibodies (VHHs) against the critical functional domain of anthrax protective antigen (PA)[J].Int J Biol Macromol,2018,114(7):1267-1278.
[13] Jones RM, Burke M, Dubose D, et al.Stability and pre-formulation development of a plant-produced?anthrax vaccine candidate[J].Vaccine,2017,35(41):5463-5470. |
